Abstract: The invention is based on a class of dual modulators of soluble epoxide hydrolase (sEH) and farnesoid X receptor (FXR), in particular of compounds having an activity as FXR agonist and sEH inhibitor for the treatment or prevention of kidney diseases and/or fibrotic diseases. The invention provides the compounds for use in such treatments and preventions as well as pharmaceutical compositions comprising the compounds as active ingredients.

Abstract: A method for producing a bearing component includes providing a bearing component blank with an iron-based metal substrate, hardening the metal substrate, treating the metal substrate by an alkaline treatment bath in a region to form an iron oxide-based blackening layer as a conversion layer with an initial layer thickness (db) on the region, and rolling a spherical body over the region to compress the conversion layer in the region to form a bearing component with a protective layer having a final layer thickness (de) that is less than 95% of the initial layer thickness (db). The spherical body may be a component part of a hydrostatic finish rolling tool or a hydrostatic deep rolling tool. The spherical body may include a hard metal or a ceramic.

Abstract: A control device within an actuator includes control logic for a second actuator, the second actuator being connected with the first actuator through a communications interface. By storing the control logic in the second actuator, the construction space for this second actuator is optimized. By integrating the control logic into a control device of the first actuator, the power density of the control device is increased.

Abstract: The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR and inhibitors (antagonists) of sEH. The invention also provides methods for treating subjects suffering from diseases associated with FXR and sEH, such as metabolic disorders, in particular non-alcoholic fatty liver or nonalcoholic steatohepatitis (NASH).